Ann: Dronabinol Supply Agreement/Sleep Apnoea Trial Update, page-18

$25 million market cap and four clinical trials in sectors that could create a company worth hundreds of millions. Again, BOT is a $150 million company with one successful phase 1a trial. The opportunity in IHL is enormous.

And don’t forget Peter Widdows is in the background with an executive pedigree that turned around Heinz Asia Pac. He is a seriously good operator so it’s no surprise IHL has evolved into an efficient operation.